Beijing Diagreat Biotechnologies Co., Ltd. (Diagreat), established in 2013, is headquartered in Beijing Economic and Technological Development Zone.  

Diagreat has a mature research and production platform for core materials upstream of in vitro diagnosis and life science. These include small molecule directional coupling technology, antibody research and production, protein engineering technology, enzyme molecular engineering technology, nucleic acid synthesis and modification, primer-probe synthesis, gene synthesis, and sequencing, etc. 

Diagreat has a variety of in vitro diagnostic products with domestic registration certificates. The main product lines include the Fluorescent Immunochromatographic - POCT series and the Chemiluminescence series, which supports Therapeutic Drug Monitoring (TDM). Our series have passed CE certification and certifications in Italy, Mexico, Ecuador, etc. These products are currently utilized in more than 60 countries and regions globally. 

Diagreat has dozens of patented inventions. We successively won the honorary titles of 'National High-tech Enterprise', 'Zhongguancun High-tech Enterprise', 'Beijing 'Specialization, Refinement, Differentiation, Innovation' of Small and Medium-sized Enterprises', 'Beijing Golden Seed Enterprise', 'Yizhuang Deloitte Top 20 growth' and other honorary titles. Diagreat has won the First Prize for Scientific and Technological Progress in Beijing, undertaken one national key scientific and technological research and development project, and has successively completed a number of key scientific and technological research and development projects in Beijing, as well as a number of regional science and technology projects.